Literature, news and videos pertinent to
The Tuyen Nguyen
Rare Cancers Program

PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
By The ASCO Post Staff
December 10, 2023 - Supplement: ESMO Highlights

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
By The ASCO Post Staff
October 10, 2022 - Supplement: Conference Highlights IASLC 2022

Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) Centers for Medicare & Medicaid Services

INHERIT EGFR - Studying Germline EGFR Mutations (INHERIT)

powered by Surfing Waves

The Tuyen Nguyen Rare Cancers Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253